Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Hyperprogressive disease (HPD) is a recognized pattern of rapid tumor progression during immune checkpoint inhibitor (ICI) treatment. Definitions of HPD have not been standardized, posing the risk of capturing different tumoral behaviors.

Objectives

To provide a systematic summary of definitions and the incidence of HPD in patients undergoing ICI treatment and discuss the challenges of current assessment of HPD.

Data sources

Articles that evaluated HPD published before March 3, 2020, were identified from MEDLINE and EMBASE.

Study selection

Clinical trials and observational studies providing the incidence and definition of HPD from patients with cancer treated with ICIs.

Data extraction and synthesis

Factors included in the analysis comprised a

SUBMITTER: Park HJ 

PROVIDER: S-EPMC7991969 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature